Fadrozole

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Fadrozole
Fadrozole structure.svg
Systematic (IUPAC) name
4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile
Clinical data
Legal status
  • ℞ (Prescription only)
Routes of
administration		 Oral
Identifiers
CAS Number 102676-31-3 YesY
ATC code none
PubChem CID: 59693
ChemSpider 53850 N
UNII H3988M64PU N
KEGG D02451 YesY
ChEMBL CHEMBL9298 N
Chemical data
Formula C14H13N3
Molecular mass 223.27 g/mol
  • C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N
  • InChI=1S/C14H13N3/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14/h4-7,9-10,14H,1-3H2 N
  • Key:CLPFFLWZZBQMAO-UHFFFAOYSA-N N
 NYesY (what is this?)  (verify)

Fadrozole (INN, marketed as Afema by Novartis) is an aromatase inhibitor[1] that has been introduced in Japan for the treatment of breast cancer.

It is selective.[2]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.

See also



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Fadrozole&oldid=5335417"